Form D · Biotechnology

Lycia Therapeutics, Inc.

South San Francisco, CA · CIK 0001806540

Offering snapshot reported Jun 25, 2026 · SEC filing

Reported sold
$75M
Offering amount: $75M
Investors reported
16
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 10, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 25, 2026Initial$75,000,000No comparison16SEC filing
May 23, 2024Initial$106,600,004No comparison16SEC filing
Sep 16, 2021Initial$70,055,062No comparison11SEC filing
Mar 17, 2020Initial$25,390,410No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-588627

Source: Form D, filed Jun 25, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tim Anderson Director
Amy Bachrodt Executive
Jeremy S. Caldwell Director, Executive
Ming Fang Director
Laurent Fischer Director
Andrew Gottesdiener Director
Clare Ozawa Director
William Rieflin Director
Aetna Wun Trombley Director, Executive
Thomas Woiwode Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
400 East Jamie Court, Suite 200
South San Francisco, CA, 94080
Phone: (650) 392-3357